New award for hydralazine HCL injections with hikma pharmaceuticals USA, INC. Ordering period is 1/20/2026 - 1/19/2027 with four one-year options.
Active Indefinite Delivery Contract Awarded Last action
- Contract number
- 36E79726D0001
- Awardee
-
Hikma Pharmaceuticals USA Inc. UEI NQJ5E87TKNB1 Part of Hikma Specialty USA Inc.
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- 6505--Hydralazine Injection Pre-Solicitation · 36E79725R0048 · Posted Jul 7, 2025
- Last date to order 79% complete
- IDV ceiling
- $2,371,481.00
- Award type
- Single award
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition after exclusion of sources · 2 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
The Department of Veterans Affairs National Acquisition Center awarded a single-award indefinite-delivery contract to Hikma Pharmaceuticals USA Inc. for Hydralazine Hydrochloride Injections with a ceiling of $2,371,481 on January 20, 2026. The procurement was conducted as a restricted competition under FAR 6.302-7 Public Interest provisions, limited to offerors proposing U.S.-made products.
The contract covers supply to the VA system, Federal Health Care Centers, and State Veterans Homes. The originating solicitation (36E79725R0048) specified 20mg/mL formulation in 1mL vials distributed through the VA's Pharmaceutical Prime Vendor Program, with an estimated annual requirement of 82,630 vials. Products are supplied with the contractor's unique National Drug Code label as the sole label on each vial, which must include a barcode. NAICS 325412 applies (Pharmaceutical Preparation Manufacturing).
The period of performance runs from January 20, 2026 through January 19, 2027, with four one-year options extending the contract through January 19, 2031. Hikma operates under NAICS 325412 and PSC 65 (Drugs and Biologicals) and holds no SBA certifications. The company supplies generic injectable and non-injectable pharmaceutical products and competes on full-and-open vehicles with no set-aside designation.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Add Subcontract Plan | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36E79726D0001?
36E79726D0001 was awarded to Hikma Pharmaceuticals USA Inc. by National Acquisition Center (Headquarters) on January 20, 2026.
How much is contract 36E79726D0001 worth?
36E79726D0001's own ceiling is $2,371,481.
Who can order from contract 36E79726D0001?
36E79726D0001 is a single award indefinite delivery contract.
Was contract 36E79726D0001 competed?
The extent of competition for 36E79726D0001 was full and open competition after exclusion of sources. The government received 2 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV